Applications, hearings, determinations, etc.: Noramco Inc.,
[Federal Register: December 27, 2007 (Volume 72, Number 247)]
[Notices]
[Page 73360]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr27de07-77]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer Of Controlled Substances; Notice Of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 6, 2007, Noramco Inc., Division of Ortho, McNeil, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:
Drug
Schedule
Codeine-N-oxide (9053)..................... I Morphine-N-oxide (9307).................... I Dihydromorphine (9145)..................... II Codeine (9050)............................. II Dihydrocodeine (9120)...................... II Oxycodone (9143)........................... II Hydromorphone (9150)....................... II Hydrocodone (9193)......................... II Morphine (9300)............................ II Thebaine (9333)............................ II Opium, raw (9600).......................... II Opium extracts (9610)...................... II Opium fluid extract (9620)................. II Opium tincture (9630)...................... II Opium, powdered (9639)..................... II Opium, granulated (9640)................... II Poppy Staw (9650).......................... II Oxymorphone (9652)......................... II Alfentanil (9737).......................... II Sufentanil (9740).......................... II Carfentanil (9743)......................... II Fentanyl (9801)............................ II
The company plans to bulk manufacture the above listed controlled substances for sale and distribution to manufacturers for product development and formulation.
Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administrator, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than February 25, 2008.
Dated: December 17, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-25045 Filed 12-26-07; 8:45 am]
BILLING CODE 4410-09-P
